Show simple item record

FieldValueLanguage
dc.contributor.authorO'Hara, Daniel Vincent
dc.date.accessioned2024-11-21T04:43:25Z
dc.date.available2024-11-21T04:43:25Z
dc.date.issued2024en_AU
dc.identifier.urihttps://hdl.handle.net/2123/33301
dc.description.abstractWithout careful management, people with type 2 diabetes mellitus (T2DM) are at risk of progressive kidney function decline, conferring increased risks of cardiovascular events, hospitalisations for complications, and impaired quality of life. Progression to kidney failure has further serious impacts upon quality of life and life expectancy. Medications such as sodium-glucose cotransporter-2 (SGLT2) inhibitors can effectively lower the risk of diabetic kidney disease (DKD), however the global impact of these agents is diminished by major challenges in evidence-based care delivery. This thesis explored practical solutions to help close the evidence-practice gap. The first part examined current evidence-based care for DKD through synthesis of rapidly evolving clinical trial data, including a meta-analysis of kidney outcomes with a class of medications used in T2DM, dipeptidyl-peptidase-4 inhibitors, showing worse preservation of kidney function than with comparator medications. The second part investigated medication adherence trends for people with T2DM commencing kidney-protective therapies. It demonstrated a critical need to support long-term adherence. The third part explored barriers and facilitators to effective diabetes care, including to SGLT2 inhibitor use, through interviews with people with T2DM and multidisciplinary clinicians. It highlighted a need to provide better patient education about T2DM, strategies to prevent medication adverse effects, and practical adherence skills. The fourth part investigated digital health technologies as scalable methods of delivering patient education and adherence support, including the design of a text message education and support program for new users of SGLT2 inhibitors, to be tested in an upcoming randomised controlled trial. This body of work has significantly advanced medical understanding of strategies to close the evidence-practice gap in T2DM care and lays important groundwork for ongoing research in this field.en_AU
dc.language.isoenen_AU
dc.subjectType 2 diabetes mellitusen_AU
dc.subjectchronic kidney diseaseen_AU
dc.subjectSGLT2 inhibitorsen_AU
dc.subjectimplementationen_AU
dc.subjectevidence-practice gapen_AU
dc.subjectadherenceen_AU
dc.titleImproving the Standard of Care in Diabetic Kidney Diseaseen_AU
dc.typeThesis
dc.type.thesisDoctor of Philosophyen_AU
dc.rights.otherThe author retains copyright of this thesis. It may only be used for the purposes of research and study. It must not be used for any other purposes and may not be transmitted or shared with others without prior permission.en_AU
usyd.facultySeS faculties schools::Faculty of Medicine and Health::NHMRC Clinical Trials Centreen_AU
usyd.degreeDoctor of Philosophy Ph.D.en_AU
usyd.awardinginstThe University of Sydneyen_AU
usyd.advisorJardine, Professor Meg


Show simple item record

Associated file/s

Associated collections

Show simple item record

There are no previous versions of the item available.